INSP SECURITIES: Inspire Medical Systems, Inc. Investors with Losses are Reminded to Contact BFA Law by January 5 Securities Fraud Class Action Deadline

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being the Inspire V, which received FDA approval on August 2, 2024 [4]. Lawsuit Details - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Inspire stock, with the case pending in the U.S. District Court for the District of Minnesota [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case [3]. Stock Performance and Issues - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," leading to a reduction in its 2025 earnings per share guidance by over 80% [7]. - The company cited undisclosed factors for the delays, including incomplete training at implanting centers and poor demand due to excess inventory of older devices [7][6]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].